Testing a new antibody drug called GNC-039 in people with glioma or other solid tumors
Official title: A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing how safe a new drug called GNC-039 is in people whose tumor has come back or spread.
Read our full plain-language summary
What the trial team says
In this study, the safety, tolerability and preliminary effectiveness of GNC-039 in patients with relapsed/refractory or metastatic glioma or other solid tumors will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-039.
Key facts
- Registry number
- NCT04794972
- Stage of testing
- Phase 1
- Conditions studied
- Recurrent Glioma, Solid Tumor
Where it is running
This trial lists 6 sites.
-
Beijing Municipality
- Beijing Tiantan Hospital, Capital Medical University (Beijing)
-
Chongqing Municipality
- Affiliated Cancer Hospital of Chongqing Medical University (Chongqing)
-
Guangdong
- ZhuJiang Hospital of Southern Medical University (Guangzhou)
- Shenzhen Second People's Hospital (Shenzhen)
-
Shanxi
- The First Affiliated Hospital of Xi'an Jiao Tong University (Xian)
-
Sichuan
- West China Hospital，Sichuan University (Chengdu)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.